u/zeynep_ndiaye

Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.

Spent an evening on the histology scoring system and understood the trial literature far better afterwards.

keep the script and the receipt for private health claims

reflux at night, try not eating in the three hours before bed

Correcting myself: the readout I quoted was the 55-week interim rather than the endpoint.

Agreed on keeping every form and date.

Agreed — write the application against the published criteria rather than around them.

PBS criteria are published and searchable

Registration by the therapeutic goods regulator establishes that a product may be supplied. Subsidy listing is a separate decision about public funding, with its own criteria and its own timetable.

Right. And the sema-to-tirz "conversion" people post is invented. There is no published equivalence.

satiety signalling rather than incretin signalling

Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes.

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

Kept a one-line-a-day log for two months.

This is the shape almost everybody here describes, and it is the single most reassuring thing in the thread.

Is it every week or did it start at a particular dose?

Correction: that is a known effect of reduced intake rather than a direct drug effect. The distinction matters because the fix is different.

Where in the fridge is it sitting now?

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Correction: that is a known effect of reduced intake rather than a direct drug effect. The distinction matters because the fix is different.

if it is severe or persistent that is a clinician question, not a board question

Not convinced. A warm pack on day six is expected behaviour from a pack designed for four.

Correction: that is a known effect of reduced intake rather than a direct drug effect. The distinction matters because the fix is different.

Careful with the supplement recommendation. There is no evidence for it here and the mechanism you are proposing does not hold.

Yes — a logger in the box turns a fortnight of speculation into a chart.

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

Hair shedding after significant weight loss is a telogen effect that follows the rate of loss. It is not specific to these compounds and it resolves.

nothing containing this is approved anywhere and research material is not for human use

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

Correcting myself: the readout I quoted was the 45-week interim rather than the endpoint.

a liver endpoint is not a weight endpoint with better marketing

interval stretching is the most commonly described approach here

Quantity limits restrict how much may be dispensed in a period even where coverage exists.

karim_restrepo is right that a rejected claim and a denied authorization are different animals.

Same. Private pricing varies here as much as anywhere and people assume it is fixed.

That is the ambient temperature at the destination, not the temperature inside the box. The logger measures the second one.

the first fortnight after a step is the worst of it, then it settles

appetite comes back before the weight does

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

the exception drug status route exists in several provinces

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.